Venlafaxine Actavis, 37.5 mg, prolonged-release hard capsules
Venlafaxine
Venlafaxine Actavis contains the active substance venlafaxine. Venlafaxine Actavis is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions, such as anxiety disorders. The mechanism of action of antidepressants is not fully understood, but they may help by increasing the levels of serotonin and noradrenaline in the brain. Venlafaxine Actavis is used to treat depression in adults. It is also indicated for the treatment of the following anxiety disorders in adults: generalized anxiety disorder, social anxiety disorder (fear or avoidance of social situations), and panic attacks. For the patient to feel better, it is essential that the treatment of depression and anxiety disorders is carried out properly. If left untreated, the patient's condition may not improve, worsen, and become more difficult to treat.
Actavis (see also "Important information before taking Venlafaxine Actavis" and the information in this section about serotonin syndrome).
Beforestarting to take Venlafaxine Actavis, you should discuss it with your doctor or pharmacist:
Venlafaxine Actavis may cause feelings of anxiety or inability to sit or stand still in the first few weeks of treatment. If such symptoms occur, you should inform your doctor. Do not drink alcohol while taking Venlafaxine Actavis, as it may cause extreme fatigue and loss of consciousness. Taking it with alcohol and/or certain medicines may increase the symptoms of depression and other conditions, such as anxiety disorders. Suicidal thoughts and worsening of depression or anxiety disorders Patients with depression and/or anxiety disorders may sometimes have thoughts of self-harm or suicide. Such thoughts may worsen at the start of treatment with antidepressants, as these medicines start to work usually after 2 weeks, sometimes later. These thoughts may also occur when reducing the dose or stopping treatment with venlafaxine. The occurrence of suicidal thoughts, self-harm, or suicidal behavior is more likely if:
If you experience suicidal thoughts or self-harm, you should immediately contact your doctor or go to the emergency department of the nearest hospital. It may be helpful to inform your family or friends about your depression or anxiety disorder and ask them to read this leaflet. You may ask your family or friends for help and ask them to inform you if they notice that your depression or anxiety has worsened or if there are any worrying changes in your behavior. Dry mouth Dry mouth was reported by 10% of patients treated with venlafaxine. This may increase the risk of tooth decay. Therefore, you should pay special attention to oral hygiene. Diabetes Blood sugar levels may change when taking Venlafaxine Actavis. Therefore, it may be necessary to adjust the dosage of antidiabetic medicines. Sexual dysfunction Medicines like Venlafaxine Actavis (so-called SNRIs) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms persisted after stopping treatment.
Venlafaxine Actavis should not normally be used in children and adolescents under 18 years of age. It should be noted that in the case of taking medicines of this class, patients under 18 years of age are at increased risk of side effects, such as suicidal attempts, suicidal thoughts, and hostility (especially aggression, rebellious behavior, and manifestations of anger). Nevertheless, the doctor may prescribe Venlafaxine Actavis to patients under 18 years of age, considering that it is in their best interest. If the doctor has prescribed Venlafaxine Actavis to a patient under 18 years of age and there are any doubts, you should consult the doctor. There is a lack of available data on the long-term safety of this medicine in this age group regarding growth, maturation, and cognitive and behavioral development.
You should tell your doctor or pharmacist about all medicines you are taking now or have taken recently, as well as any medicines you plan to take. Your doctor will decide whether it is possible to take Venlafaxine Actavis with other medicines. Do not start or stop taking other medicines, including those available without a prescription, herbal, or dietary supplements, without consulting your doctor or pharmacist first.
Examples of such medicines include:
Subjective and objective symptoms of serotonin syndrome may include a combination of the following symptoms: restlessness, hallucinations, loss of coordination, rapid heartbeat, elevated body temperature, rapid changes in blood pressure, overreactivity, diarrhea, coma, nausea, vomiting. The most severe form of serotonin syndrome can resemble neuroleptic malignant syndrome. Its symptoms include: fever, rapid heartbeat, sweating, muscle stiffness, disorientation, increased levels of muscle enzymes (detected in blood tests). If serotonin syndrome is suspected, you should immediately tell your doctor or go to the emergency department of the nearest hospital.
Venlafaxine Actavis should be taken with food (see section 3 "How to take Venlafaxine Actavis"). Do not drink alcohol while taking Venlafaxine Actavis. Taking it with alcohol may cause extreme fatigue and loss of consciousness, as well as worsen the symptoms of depression and other conditions, such as anxiety disorders.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before taking this medicine. Pregnancy Venlafaxine Actavis should only be used after discussing the potential benefits and risks to the unborn child with your doctor. You should inform your doctor and/or midwife about taking Venlafaxine Actavis. Taking medicines like Venlafaxine Actavis during pregnancy may increase the risk of severe complications in the newborn, called persistent pulmonary hypertension of the newborn (PPHN), which is characterized by rapid breathing and blue discoloration. These symptoms usually occur within the first day of life. If such symptoms occur in the newborn, you should immediately contact the midwife and/or doctor. If you take this medicine during pregnancy, after the baby is born, in addition to breathing difficulties, other symptoms may occur, such as problems with sucking. If you are concerned about such symptoms in the newborn, you should contact the doctor and/or midwife, who will be able to provide proper advice. Taking Venlafaxine Actavis at the end of pregnancy may increase the risk of severe vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. If you take Venlafaxine Actavis, you should inform your doctor or midwife so that they can provide you with proper advice. Breastfeeding Venlafaxine Actavis passes into breast milk. There is a risk of affecting the baby. Therefore, you should discuss this with your doctor, and the doctor will decide whether to stop breastfeeding or discontinue this medicine.
You should not drive or operate machinery until you know how the medicine affects you.
If you have been told that you have an intolerance to some sugars, you should contact your doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per capsule, which means it is essentially "sodium-free".
The medicine may cause allergic reactions.
The medicine may cause allergic reactions.
This medicine should always be taken as directed by your doctor. If you are unsure, you should ask your doctor or pharmacist. The usual recommended starting dose for the treatment of depression, generalized anxiety disorder, social anxiety disorder is 75 mg per day. This dose may be gradually increased by your doctor if necessary, up to a maximum dose of 375 mg per day in the case of depression. In the case of panic attacks, treatment should be started with a lower dose (37.5 mg) and then gradually increased. The maximum dose for the treatment of generalized anxiety disorder, social anxiety disorder, and panic disorder is 225 mg per day. Venlafaxine Actavis should be taken once a day, at approximately the same time, regardless of whether the medicine is taken in the morning or evening. The capsules should be swallowed whole with a drink of water, without dividing, crushing, chewing, or dissolving them. Venlafaxine Actavis should be taken with food. If you have liver or kidney problems, you should inform your doctor, as it may be necessary to adjust the dose. Do not stop taking this medicine without consulting your doctor (see "Stopping Venlafaxine Actavis").
In case of overdose, you should immediately contact your doctor or pharmacist. Overdose can be life-threatening, especially when taken with alcohol and/or certain medicines (see "Venlafaxine Actavis with other medicines"). Symptoms of possible overdose may include rapid heartbeat, changes in consciousness (from drowsiness to coma), changes in vision, seizures, and vomiting.
If you forget to take a dose, you should take the next capsule as soon as possible. However, if it is almost time for the next dose, you should skip the missed dose and take only one dose at the usual time. Do not take a double dose to make up for the missed dose. Do not take more than the daily dose of Venlafaxine Actavis prescribed by your doctor in one day.
You should not stop treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor decides that you can stop taking Venlafaxine Actavis, they will tell you how to gradually reduce the dose before completely stopping treatment. In patients stopping this medicine, especially when treatment is stopped abruptly or the dose is reduced too quickly, side effects may occur. Some patients may experience symptoms such as suicidal thoughts, aggressive behavior, fatigue, dizziness, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, restlessness, confusion, ringing in the ears, tingling or numbness, weakness, sweating, seizures, or flu-like symptoms, and changes in vision and increased blood pressure (which may cause headache, dizziness, ringing in the ears, sweating, etc.). Your doctor will advise you on how to gradually stop taking Venlafaxine Actavis. This may take several weeks or months. In some patients, it may be necessary to stop the medicine very gradually over a period of months or longer. If you experience any of the above symptoms or other symptoms that are troublesome to you, you should consult your doctor. If you have any further questions about taking this medicine, you should ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You should tell your doctorif you experience other side effects, such as (the frequency of these side effects is listed below in the "Other side effects" section):
Venlafaxine Actavis may sometimes cause side effects that you are not aware of, such as increased blood pressure or abnormal heart rhythm; slight changes in sodium, cholesterol, or liver enzyme levels in the blood. Even more rarely, Venlafaxine Actavis may affect platelet function, leading to an increased risk of bruising or bleeding. Therefore, your doctor may recommend a blood test from time to time, especially during long-term treatment with Venlafaxine Actavis.
If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel. +48 22 49 21 301, fax: +48 22 49 21 309 Website: https://smz.ezdrowie.gov.pl By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children. Do not take Venlafaxine Actavis after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month. There are no special storage precautions. Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
37.5 mg: gelatin, sodium lauryl sulfate, dyes: cochineal red (E 124), quinoline yellow (E 104), titanium dioxide (E 171) 75 mg: gelatin, sodium lauryl sulfate, dyes: orange yellow (E 110), quinoline yellow (E 104), titanium dioxide (E 171) 150 mg: gelatin, sodium lauryl sulfate, dyes: orange yellow (E 110), quinoline yellow (E 104), patent blue (E 131), titanium dioxide (E 171)
Venlafaxine Actavis 37.5 mg, prolonged-release hard capsules: white to almost white pellets in a size "3" capsule with an orange cap and a transparent body. Venlafaxine Actavis 75 mg, prolonged-release hard capsules: white to almost white pellets in a size "1" capsule with a yellow cap and a transparent body. Venlafaxine Actavis 150 mg, prolonged-release hard capsules: white to almost white pellets in a size "0" capsule with a light yellow cap and a transparent body. The prolonged-release hard capsules are available in PVC/Aluminum blisters. Pack sizes: 28 capsules packaged in blisters (PVC/Aluminum). 30 capsules packaged in blisters (PVC/Aluminum).
Actavis Group PTC ehf. Dalshraun 1 220 Hafnarfjörður Iceland
Balkanpharma – Dupnitsa AD 3 Samokovsko Shosse Str. 2600 Dupnitsa Bulgaria
Teva Pharmaceuticals Polska Sp. z o.o., ul. Emilii Plater 53, 00-113 Warsaw, tel. (22) 345 93 00. Date of last revision of the leaflet:February 2024.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.